Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych |

URPLWMiPB

URPLWMiPB

124rd meeting of the Management Board of the European Medicines Agency

30/08/2024
Communication of the President of the Office of 4th June 2024 on the publication of the 2023 Annual Report of the European Medicines Agency (EMA), providing details of the Agency's contribution to public health and animal health in the EU.

04/06/2024
Communication of the President of the Office of 21st May 2024 on the PRAC Committee's recommendation to suspend marketing authorizations for medicines containing 17-hydroxyprogesterone capronate (17-OHPC) in the European Union.

21/05/2024
123rd meeting of the Management Board of the European Medicines Agency

26/03/2024
122nd meeting of the Management Board of the European Medicines Agency

18/12/2023
Communication of the President of the Office of 4.12.2023 on the recommendation of the PRAC Committee regarding new risk minimization measures to reduce the occurrence of serious adverse reactions of medicinal products containing pseudoephedrine

04/12/2023
Communication of the President of the Office, of the 14th of September 2023, on the recommendation of the CHMP Committee (EMA) for the marketing authorization of the adapted Spikevax vaccine against Covid-19, targeting the Omicron subvariant XBB.1.5.

14/09/2023